C

Liquidia Corporation LQDA

$54.43 -$2.20-3.89% NASDAQ
Recommendation
Dividend Power Score
Day's Range
$53.97$57.21
Latest Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
My Lists My Alerts
Access our Premium Ratings
Get Access

LQDA Rating

Reward
Risk

LQDA Rating Factors

Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index

LQDA Company Overview

Liquidia Corporation is a U.S.-based biopharmaceutical company focused on the development, manufacturing, and commercialization of therapies for rare cardiopulmonary diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on pulmonary arterial hypertension (PAH) and related pulmonary conditions. Liquidia’s core business centers on leveraging its proprietary PRINT technology platform, a particle engineering and drug delivery technology designed to produce precisely engineered particles for inhaled therapeutics and other pharmaceutical applications.

The company’s primary revenue drivers are product commercialization activities, licensing arrangements, and development-stage therapeutic programs. Liquidia is best known for YUTREPIA, an inhaled dry-powder formulation of treprostinil intended for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), subject to ongoing regulatory and legal developments. Liquidia evolved through a combination of technology platform development and strategic acquisitions, including the acquisition of RareGen, LLC, which expanded its commercial infrastructure and rights related to pulmonary hypertension therapies. The company positions itself competitively through its proprietary drug delivery capabilities, focus on orphan diseases, and specialization in inhaled therapies targeting underserved patient populations.

Data compiled by narrative technology. May contain errors.
Sector

LQDA Income Statement

Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)

LQDA Balance Sheet

Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)

LQDA Cash Flow

Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)

LQDA Price History

Loading...
52-Week Range45% of range
Current
$54.43
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return

LQDA Valuation

Market Cap
Market Cap Rank
#3,578
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)

LQDA Dividends and Shares

Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--

LQDA Corporate Info

Phone Number
919 328 4400
Address
419 Davis Drive
Suite 100
Morrisville, NC 27560
Country
Year Founded

LQDA Filings

Filing Date
Tuesday, November 10, 2026
Period Date
Wednesday, September 30, 2026
Next Filing
Week of Mar 1 and 5 (est)

LQDA Headlines

11/14/2026 - Seeking Alpha - Long Ideas
11/11/2026 - Zacks Investment Research